Rani Therapeutics
RANI
34 hedge funds and large institutions have $17.6M invested in Rani Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 32 → 34 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.04% less ownership
Funds ownership: 12.96% → 11.93% (-1%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
42% less capital invested
Capital invested by funds: $30.4M → $17.6M (-$12.8M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$280K |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
+$247K |
| 3 |
PCIA
Prime Capital Investment Advisors
Overland Park,
Kansas
|
+$244K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$132K |
| 5 |
E
Ergoteles
New York
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
-$1.49M |
| 2 |
BlackRock
New York
|
-$1.02M |
| 3 |
ISB
Iowa State Bank
Urbandale,
Iowa
|
-$181K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$179K |
| 5 |
Millennium Management
New York
|
-$117K |
RANI Hedge Fund Activity: Q4 2022 in Review
34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q4 2022, worth a combined $17.6M — down 42% from $30.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RANI positions and 6 closed out — a net gain of 2 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $280K. The largest seller was Alphabet Inc, cutting an estimated $1.49M.
- 34 institutional investors held Rani Therapeutics (RANI) as of Q4 2022, up from 32 in Q3 2022.
- Funds reported $17.6M of Rani Therapeutics stock for Q4 2022, down 42% quarter-over-quarter.
- 8 funds opened new Rani Therapeutics positions in Q4 2022 and 6 closed out, a net change of +2 holders.
- The largest Rani Therapeutics buyer in Q4 2022 was Renaissance Technologies, an estimated $280K added.
- The largest Rani Therapeutics seller in Q4 2022 was Alphabet Inc, an estimated $1.49M sold.
Based on aggregated 13F filings for Q4 2022.